NCT02730546View on ClinicalTrials.gov

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 24, 2016

Primary Completion Date

July 1, 2021

Study Completion Date

October 31, 2023

Conditions
Gastric Cardia AdenocarcinomaGastroesophageal Junction AdenocarcinomaStage IB Gastric Cancer AJCC v7Stage II Gastric Cancer AJCC v7Stage IIA Gastric Cancer AJCC v7Stage IIB Gastric Cancer AJCC v7Stage IIIA Gastric Cancer AJCC v7Stage IIIB Gastric Cancer AJCC v7
Interventions
DRUG

Carboplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Fluorouracil

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leucovorin Calcium

Given IV

DRUG

Oxaliplatin

Given IV

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

RADIATION

Radiation Therapy

Undergo radiation therapy

PROCEDURE

Therapeutic Conventional Surgery

Undergo curative-intent surgery

Trial Locations (2)

55905

Mayo Clinic, Rochester

85054

Mayo Clinic Hospital, Phoenix

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT02730546 - Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | Biotech Hunter | Biotech Hunter